Anfield Capital Management’s Definium Therapeutics DFTX Stock Holding History

Anfield Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$680	Buy	+36	New	+$611	﹤0.01%	649
2025 Q4	–	Sell	-36	Closed	-$424	–	595
2025 Q3	$424	Hold	36	–	–	﹤0.01%	566
2025 Q2	$234	Hold	36	–	–	﹤0.01%	499
2025 Q1	$211	Hold	36	–	–	﹤0.01%	441
2024 Q4	$251	Hold	36	–	–	﹤0.01%	414
2024 Q3	$205	Hold	36	–	–	﹤0.01%	424
2024 Q2	$260	Buy	+36	New	+$315	﹤0.01%	371
2021 Q3	–	Sell	-37	Closed	-$2K	–	205
2021 Q2	$2K	Buy	+37	New	+$1.94K	﹤0.01%	200

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Anfield Capital Management's DFTX Position: Q1 2026 in Review

Anfield Capital Management opened a new position in Definium Therapeutics (DFTX) in Q1 2026: 36 shares worth $680. The stake represents ﹤0.01% of the portfolio and ranks #649 among its holdings. This is a return to the name: Anfield Capital Management previously reported a position in DFTX as recently as Q3 2025.

Anfield Capital Management first reported a position in DFTX in Q2 2021 and has held it in 8 quarters since. The position peaked at $2K in Q2 2021. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

Anfield Capital Management held 36 shares of Definium Therapeutics worth $680 as of Q1 2026.
Definium Therapeutics was a new Anfield Capital Management position in Q1 2026.
Definium Therapeutics made up ﹤0.01% of Anfield Capital Management's portfolio in Q1 2026, its #649 holding.
Anfield Capital Management first reported a position in Definium Therapeutics in Q2 2021 and has held it in 8 quarters since.
Anfield Capital Management's Definium Therapeutics position peaked at $2K in Q2 2021.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.